AU2021103482A4 - Amino acids and peptide conjugates of dopamine - Google Patents
Amino acids and peptide conjugates of dopamine Download PDFInfo
- Publication number
- AU2021103482A4 AU2021103482A4 AU2021103482A AU2021103482A AU2021103482A4 AU 2021103482 A4 AU2021103482 A4 AU 2021103482A4 AU 2021103482 A AU2021103482 A AU 2021103482A AU 2021103482 A AU2021103482 A AU 2021103482A AU 2021103482 A4 AU2021103482 A4 AU 2021103482A4
- Authority
- AU
- Australia
- Prior art keywords
- amino
- phenyl
- ethyl
- dihydroxy
- dopamine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 title claims abstract description 40
- 229960003638 dopamine Drugs 0.000 title claims abstract description 20
- 150000001413 amino acids Chemical class 0.000 title claims abstract description 15
- 239000000863 peptide conjugate Substances 0.000 title claims description 5
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 30
- 238000003786 synthesis reaction Methods 0.000 claims abstract description 30
- 150000001875 compounds Chemical class 0.000 claims abstract description 21
- -1 compounds amino acids Chemical class 0.000 claims description 31
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 6
- LDALKGSQOBRAOA-UHFFFAOYSA-N 2-amino-N-[2-(3,4-dihydroxyphenyl)ethyl]propanamide Chemical compound CC(N)C(=O)NCCC1=CC=C(O)C(O)=C1 LDALKGSQOBRAOA-UHFFFAOYSA-N 0.000 claims description 3
- NBYUYHYHFPOSLI-UHFFFAOYSA-N 2-amino-n-[2-(3,4-dihydroxyphenyl)ethyl]-3-phenylpropanamide Chemical compound C=1C=C(O)C(O)=CC=1CCNC(=O)C(N)CC1=CC=CC=C1 NBYUYHYHFPOSLI-UHFFFAOYSA-N 0.000 claims description 3
- DHCMWEQZIBWWPX-UHFFFAOYSA-N 2-amino-n-[2-(3,4-dihydroxyphenyl)ethyl]acetamide Chemical compound NCC(=O)NCCC1=CC=C(O)C(O)=C1 DHCMWEQZIBWWPX-UHFFFAOYSA-N 0.000 claims description 3
- KGZWXTYWZFMLSQ-UHFFFAOYSA-N 3-amino-N-[2-(3,4-dihydroxyphenyl)ethyl]propanamide Chemical compound NCCC(=O)NCCC1=CC=C(O)C(O)=C1 KGZWXTYWZFMLSQ-UHFFFAOYSA-N 0.000 claims 1
- PGDYZYHRWRDRQN-UHFFFAOYSA-N 4-amino-N-[2-(3,4-dihydroxyphenyl)ethyl]butanamide Chemical compound NCCCC(=O)NCCC1=CC=C(O)C(O)=C1 PGDYZYHRWRDRQN-UHFFFAOYSA-N 0.000 claims 1
- 238000000921 elemental analysis Methods 0.000 abstract description 9
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract description 4
- 108010016626 Dipeptides Proteins 0.000 abstract description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 abstract description 3
- 230000008499 blood brain barrier function Effects 0.000 abstract description 2
- 210000001218 blood-brain barrier Anatomy 0.000 abstract description 2
- 230000035699 permeability Effects 0.000 abstract 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 66
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 66
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 56
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 42
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 36
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 33
- ADFXKUOMJKEIND-UHFFFAOYSA-N 1,3-dicyclohexylurea Chemical compound C1CCCCC1NC(=O)NC1CCCCC1 ADFXKUOMJKEIND-UHFFFAOYSA-N 0.000 description 28
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 28
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 24
- 239000000203 mixture Substances 0.000 description 23
- 239000011541 reaction mixture Substances 0.000 description 22
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 16
- 238000001816 cooling Methods 0.000 description 16
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 16
- CTENFNNZBMHDDG-UHFFFAOYSA-N Dopamine hydrochloride Chemical compound Cl.NCCC1=CC=C(O)C(O)=C1 CTENFNNZBMHDDG-UHFFFAOYSA-N 0.000 description 15
- 229960001149 dopamine hydrochloride Drugs 0.000 description 15
- 239000000284 extract Substances 0.000 description 14
- 239000012258 stirred mixture Substances 0.000 description 14
- 229940024606 amino acid Drugs 0.000 description 13
- 235000001014 amino acid Nutrition 0.000 description 13
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 12
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
- 239000000562 conjugate Substances 0.000 description 11
- 229940086542 triethylamine Drugs 0.000 description 11
- 208000018737 Parkinson disease Diseases 0.000 description 10
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 8
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 8
- 239000000706 filtrate Substances 0.000 description 8
- 239000012044 organic layer Substances 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 8
- JJMDCOVWQOJGCB-UHFFFAOYSA-N 5-aminopentanoic acid Chemical compound [NH3+]CCCCC([O-])=O JJMDCOVWQOJGCB-UHFFFAOYSA-N 0.000 description 6
- 125000003277 amino group Chemical group 0.000 description 6
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 6
- 229910052799 carbon Inorganic materials 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- ZYJPUMXJBDHSIF-NSHDSACASA-N (2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoic acid Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 ZYJPUMXJBDHSIF-NSHDSACASA-N 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 229940124277 aminobutyric acid Drugs 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 4
- 229960004502 levodopa Drugs 0.000 description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 4
- 235000019341 magnesium sulphate Nutrition 0.000 description 4
- QVDXUKJJGUSGLS-LURJTMIESA-N methyl L-leucinate Chemical compound COC(=O)[C@@H](N)CC(C)C QVDXUKJJGUSGLS-LURJTMIESA-N 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- 239000003208 petroleum Substances 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 229910052938 sodium sulfate Inorganic materials 0.000 description 4
- 235000011152 sodium sulphate Nutrition 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- RERZNCLIYCABFS-UHFFFAOYSA-N Harmaline hydrochloride Natural products C1CN=C(C)C2=C1C1=CC=C(OC)C=C1N2 RERZNCLIYCABFS-UHFFFAOYSA-N 0.000 description 3
- 229960002684 aminocaproic acid Drugs 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 229940000635 beta-alanine Drugs 0.000 description 3
- 230000021615 conjugation Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 2
- BXNJHAXVSOCGBA-UHFFFAOYSA-N Harmine Chemical compound N1=CC=C2C3=CC=C(OC)C=C3NC2=C1C BXNJHAXVSOCGBA-UHFFFAOYSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- SZBJWIUGNGNAHM-UHFFFAOYSA-N NC(CC1=CNC2=C1C=CC=C2)C(NCCC(C=C1O)=CC=C1O)=O Chemical compound NC(CC1=CNC2=C1C=CC=C2)C(NCCC(C=C1O)=CC=C1O)=O SZBJWIUGNGNAHM-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000005452 bending Methods 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- DNSISZSEWVHGLH-UHFFFAOYSA-N butanamide Chemical compound CCCC(N)=O DNSISZSEWVHGLH-UHFFFAOYSA-N 0.000 description 2
- KBPLFHHGFOOTCA-UHFFFAOYSA-N caprylic alcohol Natural products CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 238000002329 infrared spectrum Methods 0.000 description 2
- KUGLDBMQKZTXPW-JEDNCBNOSA-N methyl (2s)-2-amino-3-methylbutanoate;hydrochloride Chemical compound Cl.COC(=O)[C@@H](N)C(C)C KUGLDBMQKZTXPW-JEDNCBNOSA-N 0.000 description 2
- SWVMLNPDTIFDDY-FVGYRXGTSA-N methyl (2s)-2-amino-3-phenylpropanoate;hydrochloride Chemical compound Cl.COC(=O)[C@@H](N)CC1=CC=CC=C1 SWVMLNPDTIFDDY-FVGYRXGTSA-N 0.000 description 2
- 150000004702 methyl esters Chemical class 0.000 description 2
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- SZXBQTSZISFIAO-ZETCQYMHSA-N (2s)-3-methyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]butanoic acid Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)OC(C)(C)C SZXBQTSZISFIAO-ZETCQYMHSA-N 0.000 description 1
- QJCNLJWUIOIMMF-YUMQZZPRSA-N (2s,3s)-3-methyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]pentanoic acid Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)OC(C)(C)C QJCNLJWUIOIMMF-YUMQZZPRSA-N 0.000 description 1
- VRPJIFMKZZEXLR-UHFFFAOYSA-N 2-[(2-methylpropan-2-yl)oxycarbonylamino]acetic acid Chemical compound CC(C)(C)OC(=O)NCC(O)=O VRPJIFMKZZEXLR-UHFFFAOYSA-N 0.000 description 1
- QVHJQCGUWFKTSE-UHFFFAOYSA-N 2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound OC(=O)C(C)NC(=O)OC(C)(C)C QVHJQCGUWFKTSE-UHFFFAOYSA-N 0.000 description 1
- WCFJUSRQHZPVKY-UHFFFAOYSA-N 3-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound CC(C)(C)OC(=O)NCCC(O)=O WCFJUSRQHZPVKY-UHFFFAOYSA-N 0.000 description 1
- GFMRZAMDGJIWRB-UHFFFAOYSA-N 5-[(2-methylpropan-2-yl)oxycarbonylamino]pentanoic acid Chemical compound CC(C)(C)OC(=O)NCCCCC(O)=O GFMRZAMDGJIWRB-UHFFFAOYSA-N 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- NFVNYBJCJGKVQK-ZDUSSCGKSA-N N-[(Tert-butoxy)carbonyl]-L-tryptophan Chemical compound C1=CC=C2C(C[C@H](NC(=O)OC(C)(C)C)C(O)=O)=CNC2=C1 NFVNYBJCJGKVQK-ZDUSSCGKSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 241000208125 Nicotiana Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 206010030312 On and off phenomenon Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- MCRWZBYTLVCCJJ-DKALBXGISA-N [(1s,3r)-3-[[(3s,4s)-3-methoxyoxan-4-yl]amino]-1-propan-2-ylcyclopentyl]-[(1s,4s)-5-[6-(trifluoromethyl)pyrimidin-4-yl]-2,5-diazabicyclo[2.2.1]heptan-2-yl]methanone Chemical compound C([C@]1(N(C[C@]2([H])C1)C(=O)[C@@]1(C[C@@H](CC1)N[C@@H]1[C@@H](COCC1)OC)C(C)C)[H])N2C1=CC(C(F)(F)F)=NC=N1 MCRWZBYTLVCCJJ-DKALBXGISA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 230000000648 anti-parkinson Effects 0.000 description 1
- 229940082992 antihypertensives mao inhibitors Drugs 0.000 description 1
- 239000000939 antiparkinson agent Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- HOPSCVCBEOCPJZ-UHFFFAOYSA-N carboxymethyl(trimethyl)azanium;chloride Chemical compound [Cl-].C[N+](C)(C)CC(O)=O HOPSCVCBEOCPJZ-UHFFFAOYSA-N 0.000 description 1
- 150000001793 charged compounds Chemical class 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 210000002932 cholinergic neuron Anatomy 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 238000006114 decarboxylation reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 210000005064 dopaminergic neuron Anatomy 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003517 fume Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- VJHLDRVYTQNASM-UHFFFAOYSA-N harmine Natural products CC1=CN=CC=2NC3=CC(=CC=C3C=21)OC VJHLDRVYTQNASM-UHFFFAOYSA-N 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N n-Octanol Natural products CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
- 230000001722 neurochemical effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 229960005190 phenylalanine Drugs 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 229940080818 propionamide Drugs 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- 210000003523 substantia nigra Anatomy 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
- C07C237/08—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C07K5/06043—Leu-amino acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C07K5/06052—Val-amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention relates to the synthesis of series of novel amino acids and dipeptides
conjugates of dopamine. Apart from this we also synthesized highly lipophilic conjugates of
dopamine by increasing the number of carbon chain between amino-carboxylic group. It was
an attempt to enhance the bioavailability of dopamine by increasing its permeability through
blood brain barrier. The purity of all the prepared compounds were checked by TLC and
elemental analyses. The spectroscopical data (UV, IR, 1H-NMR, MS and elemental analysis)
of all the synthesized compounds were found in agreement with assigned molecular structures
Description
[001] The present invention relates to the synthesis of series of novel amino acids and dipeptides conjugates of dopamine.
[002] Category of neurodegenerative diseases includes Alzheimer disease, Parkinson's disease, Huntington disease, and amyotrophic lateral sclerosis. These devastating illnesses are Parkinson's disease is a common neurodegenerative disease. The vast characterized by the progressive loss of selected neurons in discrete brain areas, resulting in characterize disorders of movement, cognition, or both. For example, Alzheimer disease is characterized by the loss of cholinergic neurons in the nucleus basalis of Maynert, whereas Parkinson disease is associated with a loss of dopaminergic neurons in the substantia niagra. The most prevalent of these disorders is Alzheimer, affecting some four million people. Parkinson disease is the second most frequent disorder, affecting approximately 1.5 million Americans.
[003] Epidemiology of Parkinson disease in the city of Kolkata, India: a community based study showed that the age-adjusted prevalence rate (PR) and average annual incidence rate were 52.85/100,000 and 5.71/100,000 per year, respectively. The adjusted average annual mortality rate was 2.89/100,000 per year. The relative risk of death was 8.98. The case-control study showed that tobacco chewing protected and hypertension increased PD occurrence.
[004] The Parsi community of Mumbai, India has a prevalence of Parkinson's disease of 328.3 per 100,000 populations, which is almost in excess of that found in Nebraska. This is despite India as a whole having a low prevalence due to the inhalation of Aspand seed fumes, as a part of their religion. Aspand seed is the richest natural source of two MAO Inhibitor alkaloids, harmine and harmaline, used in Parkinson's disease. Long term use of MAO inhibitors, eventually has the opposite effect, and so may cause the high prevalence of Parkinson's disease amongst the Parsi.
[005] Nearly 40 years after levodopa or L-dopa introduction, remains an effective
Pharmacotherapy in Parkinson's disease. Development of L-dopa as a therapeutic agent in PD is a rare example of a rationally predicted and logically pursued clinical treatment in a neurological disorder, based on neurochemical pathology and basic Pharmacological theory. The effectiveness of L-dopa treatment requires its penetration into the central nervous system (CNS) and local decarboxylation to DA.
[006] Although L-dopa reduces many of the motor symptoms of PD, it does not affect non-motor symptoms and does not halt the progression of the degeneration of dopamine containing neurons in the substantia nigra (Wolters, 2000). Progression of Parkinson's disease advances (4-8 years), the efficiency of L-dopa decreases over time such that many patients develop motor fluctuations ('wearing-off and 'on-off phenomena) and dyskinesias, and patients no longer exhibit a stable and predictable clinical response. Therefore, increasing amounts and frequencies of doising of L-dopa are usually necessary to maintain the initial therapeutic response. It has also been postulated that L-dopa could be toxic to dopamine containing neurons. The therapeutic advantages and disadvantages of early versus delayed tretment with L-dopa are still debated.
[007] The development of a new drug involves three approaches (1) The general screening approaches in which chemical substances from any source are tested for their effect against predetermined disease or disease state, (2) The chemical modification of existing drug substance whose biological effects are known and (3) Mimicking the nature by biochemical design, where a compound is made to exert an action in a manner similar to a known biochemical substance. Any lead compound obtained from these three approaches is usually further modified chemically to gain the biologically most potent representative of the series.
[008] In the recent scenario, advances have taken place in the field of prodrug approach of dopamine to ensure whether dopamine conjugates with various amino acids are able to cross the blood brain barrier, so that the use of levo-dopa as the precursor of dopamine could be reduced, thus minimizing the side effect of levo-dopa. Levo-dopa has the most tremendous side effects. The literature survey reveals that not much work has been done on dopamine conjugation with amino acids and peptides. Such peptides may be comprised of units, which them selves are the part of various physiological processes. Such a conjugation may be helpful for the formulation of the targated drug delivery systems of dopamine in the brain.
[009] The following prior art is being reported:
[010] SG11201704962W: The present invention relates to peptides, and amino acid and peptide conjugates, methods for making amino acid and peptide conjugates, conjugates produced by the methods, pharmaceutical compositions compris, ing the peptides and conjugates, methods of eliciting immune responses in a subject and methods of vaccinating a subject, uses of the peptides and con, jugates for the same, and uses of the peptides and conjugates in the manufac - ture of medicaments for the same.
[011] The following presents a simplified summary of the invention in order to provide a basic understanding of some aspects of the invention. This summary is not an extensive overview of the present invention. It is not intended to identify the key/critical elements of the invention or to delineate the scope of the invention. Its sole purpose is to present some concept of the invention in a simplified form as a prelude to a more detailed description of the invention presented later.
[012] An embodiment of the present invention is generally directed to the synthesis of Fourteen compounds for anti-Parkinson's activity. They have amino acids and dipeptides conjugate of dopamine. Besides, highly lipophilic conjugates of dopamine were synthesized by increasing the number of carbon chain between amino-carboxylic group (chain elongation).
[013] An embodiment of the present invention is the synthesized compounds were characterized by FTIR to identify the functional groups and 1H-NMR to identified the number and nature of protons present in the synthesized compounds.
[014] Another embodiment of the invention is the IR spectra of the compounds, the N-H stretching and bending and C=O stretching bands were observed at 3325-3276, 1635 cm-i respectively.
[015] Yet another embodiment of the invention is 1H-NMR spectra were recorded at 400.13 MHz.
[016] The following description is of exemplary embodiments only and is not intended to limit the scope, applicability or configuration of the invention in any way. Rather, the following description provides a convenient illustration for implementing exemplary embodiments of the invention. Various changes to the described embodiments may be made in the function and arrangement of the elements described without departing from the scope of the invention.
[017] various conjugates were synthesized by using conventional solution phase peptide synthesis. To obtain compounds DA-1 to DA-6, the following sequence was taken. Initially, amino group of an amino acid was protected by Boc anhydride then conjugation with dopamine hydrochloride in the presence of DCC was carried out, which was shown in Scheme.l.
00
RAHr OH HO NH 2 R OH (i) HONH NH
NH 2 HO 0
a 1
NH N HO NH HO NH2 4H HOX HDO
[018] Scheme 1. showing Synthesis of Compounds used reagents and conditions, (i) triethyl amine (2 ml) and methanol, 40 C; (ii) N, N'-Dicyclohexylcarbodiimideat 0°C (iii) 4N Hydrochloric Acid in dioxane.
[019] In the second scheme dopamine was conjugated with increasing number of carbon chain between amino-carboxylic group i.e. Beta-alanine, gama amino butyric acid, 5 amino pentanoic acid and amino caproic acid by protecting amino group with Boc anhydride. In the above compounds lipophilicity increases with increase in number of carbon atoms and synthesis was carried in the presence of DCC, which was shown in scheme 2.
0 0 NH 2 HN R OH HO H2N R OH (i)
o o o 0 HO
0 00 0 0
[020] Scheme.2. showing the Synthesis of Compounds used reagents and conditions, (i) triethyl amine (2 ml) and methanol, 40°C; (ii) N,N'-Dicyclohexylcarbodiimideat 0°C(iii) 4NHydrochloric Acidin dioxane.
[021] Inthe third scheme dopaminewas conjugated withdipeptides. Aminoacids methyl ester hydrochloride was prepared. The other amino acids were N-protected using Boc anhydride. In the next step the N-protected amino acids and amino acids methyl ester hydrochloride were conjugated in the presence of DCC, which was shown in scheme.3.
+ CH3 0H soc H2 N COOH H 2N COOCH 3 .HCI
0
NH + H 2N COOCH 3 .HCI
a N___ N__ y _
0 R 0 R __y H __, H N COOCH 3 N COOH
H H 0 R' 0 R'
[022] For determination of partition coefficients, the drug and synthesized compounds (10 mg) were taken in glass stopper tubes containing equal volumes (10 ml) of n-octanol and PBS pH 7.4. The tubes were shaken for 6 h on wrist action shaker. After 24 h, aqueous phase was assayed for the concentration using a UV-VIS spectrophotometer at corresponding absorption maxima.
[023] The purity of the compounds was checked by TLC and elemental analyses. The synthesized compounds were analyzed using UV-VIS spectrophotometer, FTIR spectrophotometer to identify the functional groups and IH-NMR to identified the number and nature of protons present in the synthesized compounds. The molecular ion peaks were identified using Mass spectral analysis.
[024] In the IR spectra of the compounds, the N-H stretching and bending and C=O stretching bands were observed at 3325-3276, 1635 cm-1 respectively. N-H stretching frequency of the -CO-NH- grouping was observed between 3360-3260 cm- 1. Structures of the compounds were further confirmed by Mass spectroscopy wherein M* and M+1 peak was obtained.
[025] Elemental analyses were carried out. The results of the elemental analysis (C, H, and N) were within 0.4% of the calculated amounts. The spectroanalytical data (UV, IR, 1H-NMR, MS and elemental analysis) of all the synthesized compounds were found in agreement with assigned molecular structures.
[026] EXAMPLE 1:
[027] Synthesis of 2-Amino-N-[2-(3, 4-dihydroxy-phenyl)-ethyl]-propionamide (DA-1)
[028] N, N'-Dicyclohexylcarbodiimide (3.09 g, 15 mmol) was added to a stirred mixture of minimum quantity of pyridine solution at 0°C of Boc-alanine (1.89 g, 10 mmol). After a period of 15 min. the reaction mixture was admixed with the pyridine solution containing dopamine hydrochloride (1.89 g, 10 mmol). The combined mixture was left stirred at room temperature for 24 h, the precipitated dicylohexylurea (DCU) was filtered and the organic extract was evaporated in vacuum. The residue was recrystallized from diethyl ether.
[029] EXAMPLE 2
[030] Synthesis of 2-Amino-N-[2-(3, 4-dihydroxy-phenyl)-ethyl]-acetamide (DA-2)
[031] N, N'-Dicyclohexylcarbodiimide (3.09 g, 15 mmol) was added to a stirred mixture of minimum quantity of pyridine solution at 0°C of Boc-glycine (1.75 g, 10 mmol). After a period of 15 min. the reaction mixture was admixed with the pyridine solution containing dopamine hydrochloride (1.89 g, 10 mmol). The combined mixture was left stirred at room temperature for 24 h, the precipitated dicylohexylurea (DCU) was filtered and the organic extract was evaporated in vacuum. The residue was recrystallized from diethyl ether.
[032] EXAMPLE 3: Synthesis of 2-Amino-N-[2-(3, 4-dihydroxy-phenyl)-ethyl]-3 phenyl-propionamide (DA-3)
[033] N, N'-Dicyclohexylcarbodiimide (3.09 g, 15 mmol) was added to a stirred mixture of minimum quantity of pyridine solution at 0°C of Boc-phenylalanine (2.65 g, 10 mmol). After a period of 15 min. the reaction mixture was admixed with the pyridine solution containing dopamine hydrochloride (1.89 g, 10 mmol). The combined mixture was left stirred at room temperature for 24 h, the precipitated dicylohexylurea (DCU) was filtered and the organic extract was evaporated in vacuum. The residue was recrystallized from diethyl ether.
[034] EXAMPLE 4: Synthesis of 2-Amino-N-[2-(3, 4-dihydroxy-phenyl)-ethyl]-3-(1H indol-3-yl)-propionamide (DA-4)
[035] N, N'-Dicyclohexylcarbodiimide (3.09 g, 15 mmol) was added to a stirred mixture of minimum quantity of pyridine solution at 0°C of Boc-tryptophane (3.04 g, 10 mmol). After a period of 15 min. the reaction mixture was admixed with the pyridine solution containing dopamine hydrochloride (1.89 g, 10 mmol). The combined mixture was left stirred at room temperature for 24 h, the precipitated dicylohexylurea (DCU) was filtered and the organic extract was evaporated in vacuum. The residue was recrystallized from diethyl ether.
[036] EXAMPLE 5: Synthesis of 2-Amino-3-methyl-pentanoic acid [2-(3, 4-dihydroxy phenyl)-ethyl]-amide (DA-5)
[037] N, N'-Dicyclohexylcarbodiimide (3.09 g, 15 mmol) was added to a stirred mixture of minimum quantity of pyridine solution at 0°C of Boc-isoleucine (2.31 g, 10 mmol). After a period of 15 min. the reaction mixture was admixed with the pyridine solution containing dopamine hydrochloride (1.89 g, 10 mmol). The combined mixture was left stirred at room temperature for 24 h, the precipitated dicylohexylurea (DCU) was filtered and the organic extract was evaporated in vacuum. The residue was recrystallized from diethyl ether.
[038] EXAMPLE 6: Synthesis of 2-Amino-N-[2-(3, 4-dihydroxy-phenyl)-ethyl]-3 methyl-butyramide (DA-6)
[039] N, N'-Dicyclohexylcarbodiimide (3.09 g, 15 mmol) was added to a stirred mixture of minimum quantity of pyridine solution at 0°C of Boc-valine (2.17 g, 10 mmol). After a period of 15 min. the reaction mixture was admixed with the pyridine solution containing dopamine hydrochloride (1.89 g, 10 mmol). The combined mixture was left stirred at room temperature for 24 h, the precipitated dicylohexylurea (DCU) was filtered and the organic extract was evaporated in vacuum. The residue was recrystallized from diethyl ether.
[040] General structure of amino acids with conjugates of dopamine
R R 5 7 H HO N 4 9610 NH 2 1 O HO 3 2
[041] Table.1. Molecular Formula, Yield, Melting point, Rf, UV, Log P and Elemental analysis (%) (C, H, N)
Co R Mol. Mol. Mass Rf UV log Element
mp formula weigh Spectr Valu Xma P al s Yield(%) t a e x Valu analysis obtaine e (0) Mp( 0 d d C) (C,H, N)
D -CH3 CiiH 16N 2 224.2 m/z, 0.44 285. 0.53 58.91, A- 03 6 224 5 9 7.19, 73 1 12.49 212 214
D -H CioH 1 4N 2 210.2 [M+1]* 0.42 269. 0.44 57.13, A- 03 3 m/z, 0 1 6.71, 78 2 211 13.33 218 220
D -CH2 -C 6H5 C 17 H 20N 2 300.3 [M+1]* 0.38 272. 1.92 67.98, A- 03 6 m/z, 5 2 6.71, 80 3 301.4 9.33
226
D -CH2 - C8H 6N C 19 H 2 1N 3 339.4 m/z, 0.41 265. 2.07 67.24, A- 03 340 5 2 6.24, 68 204 4 12.38 206
D -CH2- CH2-CH£1 4H 22N 2 266.4 m/z, 0.48 288. 1.74 63.13, A- CH3 03 266 0 2 8.33, 212 5 10.52 214 73
D CH3 C 13 H 20N 2 252.4 m/z, 0.44 274. 1.24 61.88, -CH2 A- CH3 03 252 5 3 7.99, 234 6 11.10 77 236
[042] Amino group protection of beta alanine by Boc anhydride
[043] To a solution of beta-alanine (0.89 g, 10 mmol) in triethyl amine (2 ml) and methanol (20 ml) was added Boc anhydride (3.2 g, 15 mmol) and mixture was stirred at 40 C for 6 hrs. After ter-butoxycarbonylation was complete (as evidenced by TLC using 3:1:0.5 hexane: ethyl acetate: methanol), stirring was continued for 30 min more, then the solvent was evaporated under reduced pressure and the residue was treated with ice-cold dilute HCl for 5 min and extracted immediately with Ethyl acetate. The organic layer was dried over magnesium sulphate, then filtered, and concentrated under vacuum.
[044] EXAMPLE 7: Synthesis of 3-Amino-N-[2-(3, 4-dihydroxy-phenyl)-ethyl] propionamide (DA-7)
[045] N, N'-Dicyclohexylcarbodiimide (3.09 g, 15 mmol) was added to a stirred mixture of minimum quantity of pyridine solution at 0°C of Boc-beta-alanine (1.89 g, 10 mmol).
After a period of 15 min. the reaction mixture was admixed with the pyridine solution containing dopamine hydrochloride (1.89 g, 10 mmol). The combined mixture was left stirred at room temperature for 24 h, the precipitated dicylohexylurea (DCU) was filtered and the organic extract was evaporated in vacuum. The residue was recrystallized from diethyl ether.
[046] Amino group protection of 6-amino caproic acid by Boc anhydrid
[047] To a solution of 6-amino caproic acid (1.31 g, 10 mmol) in triethyl amine (2 ml) and methanol (20 ml) was added Boc anhydride (3.2 g, 15 mmol) and mixture was stirred at 400 C for 6 hrs. After ter-butoxycarbonylation was complete (as evidenced by TLC using 3:1:0.5 hexane: ethyl acetate: methanol), stirring was continued for 30 min more, then the solvent was evaporated under reduced pressure and the residue was treated with ice-cold dilute hydrochloric acid for 5 min and extracted immediately with Ethyl acetate. The organic layer was dried over magnesium sulphate, then filtered, and concentrated under vacuum.
[048] EXAMPLE 8: Synthesis of 6-Amino-hexanoic acid [2-(3,4-dihydroxy-phenyl) ethyl]-amide (DA-8)
[049] N, N'-Dicyclohexylcarbodiimide (3.09 g, 15mmol) was added to a stirred mixture of minimum quantity of pyridine solution at 0°C of Boc-6-amino caproic acid (2.31 g, mmol). After a period of 15 min. the reaction mixture was admixed with the pyridine solution containing dopamine hydrochloride (1.89 g, 10mmol). The combined mixture was left stirred at room temperature for 24 h, the precipitated dicylohexylurea (DCU) was filtered and the organic extract was evaporated in vacuum. The residue was recrystallized from diethyl ether.
[050] Amino group protection of gama amino butyric acid by Boc anhydrid
[051] To a solution of gama amino butyric acid (10 mmol) intriethyl amine (2 ml) and methanol (20 ml) was added Boc anhydride (3.2 g, 15 mmol) and mixture was stirred at 40 C for 6 hrs. After ter-butoxycarbonylation was complete (as evidenced by TLC using 3:1:0.5 hexane: ethyl acetate: methanol), stirring was continued for 30 min more, then the solvent was evaporated under reduced pressure and the residue was treated with ice-cold dilute hydrochloric acid for 5 min and extracted immediately with ethyl acetate. The organic layer was dried over magnesium sulphate, then filtered, and concentrated under vacuum.
[052] EXAMPLE 9: Synthesis of 4-Amino-N-[2-(3, 4-dihydroxy-phenyl)-ethyl] butyramide (DA-9)
[053] N, N'-Dicyclohexylcarbodiimide (3.09 g, 15mmol) was added to a stirred mixture of minimum quantity of pyridine solution at 0°C of Boc-gama amino butyric acid (1Ommol). After a period of 15 min. the reaction mixture was admixed with the pyridine solution containing dopamine hydrochloride (1.89 g, 10mmol). The combined mixture was left stirred at room temperature for 24 h, the precipitated dicylohexylurea (DCU) was filtered and the organic extract was evaporated in vacuum. The residue was recrystallized from diethyl ether.
[054] Amino group protection of 5-amino pentanoic acid by Boc anhydrid
[055] To a solution of 5-amino pentanoic acid (1.17 g, 10 mmol) in triethyl amine (2 ml) and methanol (20 ml) was added Boc anhydride (3.2 g, 15 mmol) and mixture was stirred at 400 C for 6 hrs. After ter-butoxycarbonylation was complete (as evidenced by TLC using 3:1:0.5 hexane: ethyl acetate: methanol), stirring was continued for 30 min more, then the solvent was evaporated under reduced pressure and the residue was treated with ice-cold dilute hydrochloric acid for 5 min and extracted immediately with ethyl acetate. The organic layer was dried over magnesium sulphate, then filtered, and concentrated under vacuum.
[056] EXAMPLE 10: Synthesis of 5-Amino-pentanoic acid [2-(3, 4-dihydroxy-phenyl) ethyl]-amide (DA-10)
[057] N, N'-Dicyclohexylcarbodiimide (3.09 g, 15mmol) was added to a stirred mixture of minimum quantity of pyridine solution at 0°C of Boc-5-amino pentanoic acid (2.17 g, 1Ommol). After a period of 15 min. the reaction mixture was admixed with the pyridine solution containing dopamine hydrochloride (1.89 g, 10mmol). The combined mixture was left stirred at room temperature for 24 h, the precipitated dicylohexylurea (DCU) was filtered and the organic extract was evaporated in vacuum. The residue was recrystallized from diethyl ether.
[058] General structure of conjugates with increasing number of carbon chain between amino-carboxylic group.
HO 5 7 H 10 HO * r6N "r 'eNH 2 4 8
HO 3 0 2
[059] Table.2. Molecular Formula, Yield, Melting point, Rf, UV, Log P and Elemental analysis (%) (C, H, N)
Comps R Mol. Mol. Mass Rf UV log P Elemental formula weight Spectra Value Xmax Value analysis Yield obtained (%) (0%) Mp(0 C) (ESI MS) (C, H, N)
DA-7 - CiiH 16N2 0 3 224.25 m/z 224 0.46 285.5 0.671 58.91, CH2 - 7.19, 280 12.49 82 282
DA-8 - C 14 H 2 2N 2 0 3 266.33 [M+1]* 0.40 259.0 1.811 63.13, CH2 - m/z 267 8.33, 294 CH2 - 10.52 296 CH2 CH2
78
DA-9 CH2 - C 12 H1 iN 2 0 3 238.28 [M+1]* 0.38 272.5 1.110 60.49, CH2 - m/z 239 7.61,
80 266 11.76
DA-10 CH2 - C 13 H 20N 2 0 3 252.30 [M+1]* 0.41 265.5 1.405 61.88, CH2 - m/z 253 7.99, 214 CH2- 11.10 216 68
[060] Synthesis of phenylalanine methyl ester hydrochloride
[061] Added thionyl chloride (100 mmol, 7.43 ml) to 150 ml dry methanol drop wise with cooling (0 °C) in RBF, then added (100 mmol, 16.5 g) of phenylalanine to this solution. Reflux the solution for 4 hours. After cooling apply vacuum to get crude methyl ester hydrochloride. Triturate it with small portion of ether at 0 °C. Recrystallise from 25 ml of hot methanol by slow addition of ether followed by cooling to 0 °C. Yield-90 %, m.p.-195-200 0 C
[062] Synthesis of Boc-Phe-phe
[063] Phenylalanine methyl ester hydrochloride (10 mmol) was dissolved in Dichloromethane (20 ml). To this, triethyl amine (TEA) (2.8 ml, 0.021 mol) was added at °C and the reaction mixture was stirred for 15 min. Boc-phenyl alanine (10 mmol) in dichloromethane (20 ml) and N,N'-Dicyclohexylcarbodiimide (3.09 g, 15 mmol) were added with stirring. After 24 h, the reaction mixture was filtered and the residue was washed with dichloromethane (30 ml) and added to the filtrate. The filtrate was washed three times with 5% sodium bi carbonate and saturated sodium chloride solutions. The organic layer was dried over anhydrous sodium sulphate, filtered and evaporated in vacuum. The crude product was recrystallized from petroleum ether followed by cooling at 0 °C. Boc-phe-phe methyl ester hydrochloride was dissolved in methanol (20ml), and then added 1 N sodium hydroxide solution in excess. The solution was stirred until completed by TLC (usually 6 hr.). After that diluted hydrochloric acid was added until the mixture was neutral and precipitate was collected for further reaction.
[064] EXAMPLE 11: Synthesis of2-Amino-N-[1-{2-(3, 4-dihydroxy-phenyl)-ethyl carbamoyl}-2-phenyl-ethyl]-3-phenyl-popionamide (DA-11)
[065] N, N'-Dicyclohexylcarbodiimide (3.09 g, 15mmol) was added to a stirred mixture of minimum quantity of pyridine solution at 0°C of Boc-Phe-phe (10mmol). After a period of 15 min. the reaction mixture was admixed with the pyridine solution containing dopamine hydrochloride (1.89 g, 10mmol). The combined mixture was left stirred at room temperature for 24 h, the precipitated dicylohexylurea (DCU) was filtered and the organic extract was evaporated in vacuum. The residue was recrystallized from diethyl ether.
[066] Synthesis of leucine methyl ester hydrochloride
[067] Added thionyl chloride (100 mmol, 7.43 ml) to 150 ml dry methanol drop wise with cooling (0 °C) in RBF, then added (100 mmol, 13.1 g) of leucine to this solution. Reflux the solution for 4 hours. After cooling apply vacuum to get crude methyl ester hydrochloride. Triturate it with small portion of ether at 0 °C. Recrystallise from 25 ml of hot methanol by slow addition of ether followed by cooling to 0 °C. Yield-90 %, m.p.-165-170 0 C
[068] Synthesis of Boc-Phe-leu
[069] Leucine methyl ester hydrochloride (10 mmol) was dissolved in Dichloromethane (20 ml). To this, triethyl amine (TEA) (2.8 ml, 0.021 mol) was added at 0 °C and the reaction mixture was stirred for 15 min. Boc-phenyl alanine (10 mmol) in Dichloromethane (20 ml) and N,N'-Dicyclohexylcarbodiimide (3.09 g, 15 mmol) were added with stirring. After 24 h, the reaction mixture was filtered and the residue was washed with dichloromethane (30 ml) and added to the filtrate. The filtrate was washed three times with 5% sodium bi carbonate and saturated sodium chloride solutions. The organic layer was dried over anhydrous sodium sulphate, filtered and evaporated in vacuum. The crude product was recrystallized from petroleum ether followed by cooling at 0 °C. Boc-phe-leu methyl ester hydrochloride was dissolved in methanol (20ml), and then added 1 N Sodium hydroxide in excess. The solution was stirred until completed by TLC (usually 6 hr.). After this diluted hydrochloric acid was added until the mixture was neutral and precipitate was collected for further reaction.
[070] EXAMPLE 12: Synthesis of 2-(2-Amino-3-phenyl-propionyl amino)-4-methyl- pentanoic acid [2-(3,4-dihydroxy-phenyl)-ethyl]-amide (DA-12)
[071] N, N'-Dicyclohexylcarbodiimide (3.09 g, 15mmol) was added to a stirred mixture of minimum quantity of pyridine solution at 0°C of Boc-Phe-leu (10mmol). After a period of 15 min. the reaction mixture was admixed with the pyridine solution containing dopamine hydrochloride (1.89 g, 10mmol). The combined mixture was left stirred at room temperature for 24 h, the precipitated dicylohexylurea (DCU) was filtered and the organic extract was evaporated in vacuum. The residue was recrystallized from diethyl ether.
[072] Synthesis of leucine methyl ester hydrochloride
[073] Added thionyl chloride (100 mmol, 7.43 ml) to 150 ml dry methanol drop wise with cooling (0 °C) in RBF, then added (100 mmol, 13.1 g) of leucine to this solution. Reflux the solution for 4 hours. After cooling apply vacuum to get crude methyl °C. Recrystallise from 25 ester hydrochloride. Triturate it with small portion of ether at 0 ml of hot methanol by slow addition of ether followed by cooling to 0 °C. Yield-90 %, m.p.-165-170 0 C
[074] Synthesis of Boc-Ala-leu
[075] Leucine methyl ester hydrochloride (10 mmol) was dissolved in Dichloromethane (20 ml). To this, TEA (2.8 ml, 0.021 mol) was added at 0 °C and the reaction mixture was stirred for 15 min. Boc-phenyl alanine (10 mmol) in Dichloromethane (20 ml) and N,N' Dicyclohexylcarbodiimide (3.09 g, 15 mmol) were added with stirring. After 24 h, the reaction mixture was filtered and the residue was washed with Dichloromethane (30 ml) and added to the filtrate. The filtrate was washed three times with 5% sodium bi carbonate and saturated sodium chloride solutions. The organic layer was dried over anhydrous sodium sulphate, filtered and evaporated in vacuum. The crude product was recrystallized from petroleum ether followed by cooling at 0 °C. Boc-ala-leu methyl ester hydrochloride was dissolved in methanol (20ml), and then added 1 N sodium hydroxide in excess. The solution was stirred until completed by TLC (usually 6 hr.). After this diluted hydrochloric acid was added until the mixture was neutral and precipitate was collected for further reaction.
[076] EXAMPLE 12:
[077] Synthesis of 2-(2-Amino-propionyl amino)-4-methyl-pentanoic acid [2-(3,4 dihydroxy-phenyl)-ethyl]-amide (DA-13)
[078] N, N'-Dicyclohexylcarbodiimide (3.09 g, 15mmol) was added to a stirred mixture of minimum quantity of pyridine solution at 0°C of Boc-ala-leu (10mmol). After a period of 15 min. the reaction mixture was admixed with the pyridine solution containing dopamine hydrochloride (1.89 g, 10mmol). The combined mixture was left stirred at room temperature for 24 h, the precipitated dicylohexylurea (DCU) was filtered and the organic extract was evaporated in vacuum. The residue was recrystallized from diethyl ether.
[079] Synthesis of Valine methyl ester hydrochloride
[080] Added thionyl chloride (100 mmol, 7.43 ml) to 150 ml dry methanol drop wise with cooling (0 °C) in RBF, then added (100 mmol, 13.1 g) of Valine to this solution. Reflux the solution for 4 hours. After cooling apply vacuum to get crude methyl ester hydrochloride. Triturate it with small portion of ether at 0 °C. Recrystallise from 25 ml of hot methanol by slow addition of ether followed by cooling to 0 °C. Yield-90 %, m.p.-163-167 0 C
[081] Synthesis ofBoc-isoleu-val
[082] Valine methyl ester hydrochloride (10 mmol) was dissolved in Dichloromethane (20 ml). To this, TEA (2.8 ml, 0.021 mol) was added at 0 °C and the reaction mixture was stirred for 15 min. Boc-phenyl alanine (10 mmol) in dichloromethane (20 ml) and N,N' Dicyclohexylcarbodiimide (3.09 g, 15 mmol) were added with stirring. After 24 h, the reaction mixture was filtered and the residue was washed with dichloromethane (30 ml) and added to the filtrate. The filtrate was washed three times with 5% sodium bi carbonate and saturated sodium chloride solutions. The organic layer was dried over anhydrous sodium sulphate, filtered and evaporated in vacuum. The crude product was recrystallized from petroleum ether followed by cooling at 0 °C. Boc-isoleu-val methyl ester hydrochloride was dissolved in methanol (20ml) and then added 1 N sodium hydroxide in excess. The solution was stirred until completed by TLC (usually 6 hr.). After this diluted hydrochloric acid was added until the mixture was neutral and precipitate was collected for further reaction.
[083] EXAMPLE13: Synthesis of 2-Amino-3-methyl-pentanoic acid {1-[2-(3, 4- dihydroxy-phenyl)-ethyl carbamoyl]-2-methyl-propyl}-amide (DA-14)
[084] N, N'-Dicyclohexylcarbodiimide (3.09 g, 15mmol) was added to a stirred mixture of minimum quantity of pyridine solution at 0°C of Boc-isoleu-valine (10mmol). After a period of 15 min. the reaction mixture was admixed with the pyridine solution containing dopamine hydrochloride (1.89 g, 10mmol). The combined mixture was left stirred at room temperature for 24 h, the precipitated dicylohexylurea (DCU) was filtered and the organic extract was evaporated in vacuum. The residue was recrystallized from diethyl ether
R 0 5 7 H HO N 10 N 12 NH 2 8 H 0 R' 2
[085] General structure of dipeptide conjugate of Dopamine.
[086] Table.3 Molecular Formula, Yield, Melting point, Rf, UV, Log P and Elemental analysis (%) (C, H, N)
Comps R Mol. Mol. Mass Rf UV log P Elemental formula weight Spectra Value Xmax Value analysis Yield obtained (%) (0%) Mp(0 C) (ESI MS) (C, H, N)
DA-11 R=- C 2 6H 2 9 N 3 0 4 447.52 m/z= 0.48 288.0 1.819 69.78, CH2 - 447 6.53,9.39 312 C 6H 5 314 R'= -
CH2
C6H 5
73
DA-12 R= - C 2 3 H3 1N 3 0 4 252.4 m/z= 0.44 274.5 1.668 66.81,7.56, CH2 - 252 10.16 334 C3H 7 336 R'=
CH2
C6H 5
77
DA-13 R= - C 17 H2 7N 3 0 4 337.4 [M+1]* 0.44 274.5 1.207 60.51, CH2 - m/z 338 8.07, 12.45 304 C3H 7 306 R'=
CH3
80
DA-14 R= - C 19H 3 1N 3 0 4 365.4 [M+1]* 0.44 274.5 1.098 62.44, C3 H 7 m/z 366 8.55,11.50 346 R'= - 348 C4 H 9
85
[087] While considerable emphasis has been placed herein on the specific features of the preferred embodiment, it will be appreciated that many additional features can be added and that many changes can be made in the preferred embodiment without departing from the principles of the disclosure. These and other changes in the preferred embodiment of the disclosure will be apparent to those skilled in the art from the disclosure herein, whereby it is to be distinctly understood that the foregoing descriptive matter is to be interpreted merely as illustrative of the disclosure and not as a limitation.
Claims (3)
1. A method for synthesis of compounds comprising amino acids and peptide conjugated to dopamine for Parkinson's disorder.
2. The method as claimed in claim 1, wherein the synthesis of compounds amino acids and peptide conjugates of dopamine are synthesized by conventional phase solubility studies.
3. The compound as claimed in claim 1, wherein the compound has the formula: (i) 2-Amino-N-[2-(3, 4-dihydroxy-phenyl)-ethyl]-propionamide; (ii) 2-Amino-N-[2-(3, 4-dihydroxy-phenyl)-ethyl]-acetamide; (iii) 2-Amino-N-[2-(3,4-dihydroxy-phenyl)-ethyl]-3-phenyl-propionamide; (iv) 2-Amino-N-[2-(3,4-dihydroxy-phenyl)-ethyl]-3-(1H-indol-3-yl) propionamide; (v) 2-Amino-3-methyl-pentanoic acid [2-(3, 4-dihydroxy-phenyl)-ethyl] amide; (vi) 2-Amino-N-[2-(3,4-dihydroxy-phenyl)-ethyl]-3-methyl-butyramide; (vii) 3-Amino-N-[2-(3, 4-dihydroxy-phenyl)-ethyl]-propionamide; (viii) 6-Amino-hexanoic acid [2-(3,4-dihydroxy-phenyl)-ethyl]-amide; (ix) 4-Amino-N-[2-(3, 4-dihydroxy-phenyl)-ethyl]-butyramide; (x) 5-Amino-pentanoic acid [2-(3,4-dihydroxy-phenyl)-ethyl]-amide; (xi) 2-Amino-N-[1-{2-(3, 4-dihydroxy-phenyl)-ethyl carbamoyl}-2-phenyl ethyl]-3-phenyl-popionamide; (xii) 2-(2-Amino-3-phenyl-propionyl amino)-4-methyl-pentanoic acid [2-(3,4 dihydroxy-phenyl)-ethyl]-amide; (xiii) 2-(2-Amino-propionyl amino)-4-methyl-pentanoic acid [2-(3,4 dihydroxy-phenyl)-ethyl]-amide; and (xiv) 2-Amino-3-methyl-pentanoic acid {1-[2-(3, 4-dihydroxy-phenyl)-ethyl carbamoyl]-2-methyl-propyl}-amide.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2021103482A AU2021103482A4 (en) | 2021-06-19 | 2021-06-19 | Amino acids and peptide conjugates of dopamine |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2021103482A AU2021103482A4 (en) | 2021-06-19 | 2021-06-19 | Amino acids and peptide conjugates of dopamine |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2021103482A4 true AU2021103482A4 (en) | 2021-08-26 |
Family
ID=77369590
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2021103482A Ceased AU2021103482A4 (en) | 2021-06-19 | 2021-06-19 | Amino acids and peptide conjugates of dopamine |
Country Status (1)
Country | Link |
---|---|
AU (1) | AU2021103482A4 (en) |
-
2021
- 2021-06-19 AU AU2021103482A patent/AU2021103482A4/en not_active Ceased
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0731085B1 (en) | Stilbene derivatives and pharmaceutical compositions containing them | |
DK2989088T3 (en) | DERIVATIVES OF DOLASTATIN 10 AND AURISTATINES | |
EP3496764A1 (en) | Production of bitter principle derivatives | |
AU9288998A (en) | New npy antagonists | |
JPH11503422A (en) | Succinic acid derivatives that inhibit proteases | |
CN107810189B (en) | Process for the preparation of nitrogen mustard derivatives | |
US20100331355A1 (en) | Substituted Quinolines for the Treatment of Cancer | |
CN114685382B (en) | Quinazoline-4-amine derivative with HDACs inhibitory activity, and preparation method and application thereof | |
AU2021103482A4 (en) | Amino acids and peptide conjugates of dopamine | |
EP0241797B1 (en) | Novel spergualin-related compounds and process for producing the same | |
CN111954663A (en) | Fluorinated 4- (substituted amino) phenyl carbamate derivatives | |
US2543345A (en) | Method of preparing glutamic acid amides | |
JP3163391B2 (en) | Stilbene derivatives and anticancer agents containing the same | |
CA2226303A1 (en) | Peptide derivatives and angiotensin iv receptor agonist | |
US4452814A (en) | Nitrosourea derivatives | |
Sosnovsky et al. | In the Search for New Anticancer Drugs: 28. Synthesis and Evaluation of Highly Active Aminoxyl Labeled Amino Acid Derivatives Containing the [N;‐(2‐chloroethyl)‐N′‐nitrosoamino] carbonyl group | |
WO2016138631A1 (en) | Imidazo benzamide compounds | |
US5061787A (en) | Novel spergualin-related compounds and compositions | |
Pinto et al. | Straightforward, racemization-free synthesis of peptides with fairly to very bulky di-and trisubstituted glycines | |
US20070185072A1 (en) | Nitrogeneous polycyclic derivatives useful as chelators of metal ions and their applications | |
CN109134295B (en) | Anthracene diketone derivative and preparation method and application thereof | |
IKEDA et al. | Total syntheses of bellenamine and its isomers | |
JP3657118B2 (en) | Method for producing theanine | |
Koleva et al. | Synthesis, spectroscopic, structural and theoretical characterization of hydrogensquarate and mononuclear Au (III)-complex of dipeptide phenylalanyltyrosine | |
CN116655605A (en) | Phenylpyrazole compound, and preparation method and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FGI | Letters patent sealed or granted (innovation patent) | ||
MK22 | Patent ceased section 143a(d), or expired - non payment of renewal fee or expiry |